United States of America
Prospective observational study
Medical records
1376
consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department
Of the 1376 patients, 811 (58.9%) received hydroxychloroquine (median duration of treatment, 5 days) and 565 (41.1%) did not.
Median
23 Day
COVID-19 (severe/fatal)
346
The primary end point was a composite of intubation or death in a time-to-event analysis. Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation).
Treatment
Treatment for COVID-19
Hydroxychloroquine treatment
Not received
Treated with hydroxychloroquine
Hazard ratio
1.000 (0.760-1.320)
No
Yes
hazard ratio from the multivariable Cox proportional-hazards model, with stratification according to sex, chronic lung disease, and bodymass index, and with additional adjustment for age, race and ethnic group, insurance, current smoking, past diagnoses, current medications, vital statistics, and laboratory tests on presentation. The analysis included all 1376 patients.
none
Good